Compare PLAB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | TYRA |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1995 | 2021 |
| Metric | PLAB | TYRA |
|---|---|---|
| Price | $50.50 | $37.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $44.33 | ★ $47.50 |
| AVG Volume (30 Days) | 718.5K | ★ 831.8K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $535,276,000.00 | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | $70.41 | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $16.59 | $8.75 |
| 52 Week High | $56.00 | $40.65 |
| Indicator | PLAB | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 57.77 |
| Support Level | $46.18 | $33.81 |
| Resistance Level | $52.79 | $39.48 |
| Average True Range (ATR) | 2.38 | 2.18 |
| MACD | -0.36 | 0.28 |
| Stochastic Oscillator | 43.99 | 77.39 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.